IBRX

SEC source: 0001326110-26-000085 · wk-form4_1791324382.xml · nonDerivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,777,788

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2025.

F2 · price: Represents the weighted average share price of an aggregate total of 25,000 shares sold in the price range of $10.665 to $10.78 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001326110-26-000084 · wk-form4_1791324339.xml · derivative · entry 3

Cohen Cheryl · CIK 0001529371 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 55,979

Underlying: Common Stock · 55,979 shares

Expires 2032-06-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001326110-26-000084 · wk-form4_1791324339.xml · nonDerivative · entry 2

Cohen Cheryl · CIK 0001529371 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 100,309

F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on February 27, 2026.

SEC source: 0001326110-26-000084 · wk-form4_1791324339.xml · nonDerivative · entry 1

Cohen Cheryl · CIK 0001529371 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 181,365

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001529371-26-000008 · wk-form4_1783383979.xml · derivative · entry 3

Cohen Cheryl · CIK 0001529371 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 111,958

Underlying: Common Stock · 55,979 shares

Expires 2032-06-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001529371-26-000008 · wk-form4_1783383979.xml · nonDerivative · entry 2

Cohen Cheryl · CIK 0001529371 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 125,386

F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on February 27, 2026.

F2 · price: Represents the weighted average share price of an aggregate total of 131,210 shares sold in the price range of $9.50 to $9.52 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001529371-26-000008 · wk-form4_1783383979.xml · nonDerivative · entry 1

Cohen Cheryl · CIK 0001529371 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 256,596

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001849739-26-000014 · wk-form4_1783383927.xml · derivative · entry 5

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 124,414 shares

Expires 2033-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001849739-26-000014 · wk-form4_1783383927.xml · derivative · entry 4

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 35,064 shares

Expires 2032-06-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001849739-26-000014 · wk-form4_1783383927.xml · nonDerivative · entry 3

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026.

F2 · price: Represents the weighted average share price of an aggregate total of 159,478 shares sold in the price range of $9.00 to $9.07 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001849739-26-000014 · wk-form4_1783383927.xml · nonDerivative · entry 2

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 159,478

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001849739-26-000014 · wk-form4_1783383927.xml · nonDerivative · entry 1

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,064

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001849739-26-000011 · wk-form4_1782939871.xml · derivative · entry 12

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 124,414

Underlying: Common Stock · 300 shares

Expires 2033-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001849739-26-000011 · wk-form4_1782939871.xml · derivative · entry 11

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,064

Underlying: Common Stock · 700 shares

Expires 2032-06-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001849739-26-000011 · wk-form4_1782939871.xml · nonDerivative · entry 7

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026.

SEC source: 0001849739-26-000011 · wk-form4_1782939871.xml · nonDerivative · entry 6

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001849739-26-000011 · wk-form4_1782939871.xml · nonDerivative · entry 5

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 700

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001849739-26-000011 · wk-form4_1782939871.xml · derivative · entry 10

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 132,786

Underlying: Common Stock · 30,000 shares

Expires 2035-06-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001849739-26-000011 · wk-form4_1782939871.xml · derivative · entry 9

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 124,714

Underlying: Common Stock · 33,549 shares

Expires 2033-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001849739-26-000011 · wk-form4_1782939871.xml · derivative · entry 8

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,764

Underlying: Common Stock · 32,173 shares

Expires 2032-06-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001849739-26-000011 · wk-form4_1782939871.xml · nonDerivative · entry 4

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026.

F2 · price: Represents the weighted average share price of an aggregate total of 95,722 shares sold in the price range of $9.00 to $9.08 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001849739-26-000011 · wk-form4_1782939871.xml · nonDerivative · entry 3

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 95,722

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001849739-26-000011 · wk-form4_1782939871.xml · nonDerivative · entry 2

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 65,722

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001849739-26-000011 · wk-form4_1782939871.xml · nonDerivative · entry 1

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,173

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001647994-26-000011 · wk-form4_1782522004.xml · nonDerivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,802,788

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2025.

F2 · price: Represents the weighted average share price of an aggregate total of 25,000 shares sold in the price range of $7.875 to $7.885 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001371407-26-000003 · wk-form4_1781136707.xml · derivative · entry 1

BLASZYK MICHAEL D · CIK 0001371407 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,600

Underlying: Common Stock · 65,600 shares

Expires 2036-06-09

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders.

SEC source: 0001364846-26-000003 · wk-form4_1781136701.xml · derivative · entry 1

Wendel Bruce · CIK 0001364846 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,600

Underlying: Common Stock · 65,600 shares

Expires 2036-06-09

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders.

SEC source: 0001822674-26-000003 · wk-form4_1781136692.xml · derivative · entry 1

MAXWELL LINDA · CIK 0001822674 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,600

Underlying: Common Stock · 65,600 shares

Expires 2036-06-09

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders.

SEC source: 0001349193-26-000003 · wk-form4_1781136683.xml · derivative · entry 1

Clark Wesley · CIK 0001349193 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,600

Underlying: Common Stock · 65,600 shares

Expires 2036-06-09

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders.

SEC source: 0001529371-26-000003 · wk-form4_1781136674.xml · derivative · entry 1

Cohen Cheryl · CIK 0001529371 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,600

Underlying: Common Stock · 65,600 shares

Expires 2036-06-09

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders.

SEC source: 0001849739-26-000007 · wk-form4_1781136666.xml · derivative · entry 1

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,600

Underlying: Common Stock · 65,600 shares

Expires 2036-06-09

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders.

SEC source: 0001647994-26-000008 · wk-form4_1780694977.xml · nonDerivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,827,788

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2025.

F2 · price: Represents the weighted average share price of an aggregate total of 23,033 shares sold in the price range of $7.125 to $7.225 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001189020-26-000008 · wk-form4_1775174919.xml · derivative · entry 10

SOON-SHIONG PATRICK · CIK 0001189020 · Director · See remarks · 10% owner

CALIFORNIA CAPITAL EQUITY, LLC · CIK 0001517764 · 10% owner

Cambridge Equities, LP · CIK 0001629222 · 10% owner

MP 13 Ventures, LLC · CIK 0001629186 · 10% owner

Nant Capital, LLC · CIK 0001675758 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: Not disclosed

Underlying: Common Stock · Not disclosed shares

Expires 2027-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · kind: Nant Capital has the right at any time after December 10, 2024 and on or before December 31, 2027 to convert all or a portion of the outstanding principal amount of this Second Amended and Restated Promissory Note, as amended January 23, 2026, into fully paid and nonassessable shares of the Issuer's common stock at a price per share equal to $5.427. On March 31, 2026, Nant Capital delivered notice to the Issuer electing to convert outstanding principal in the amount of $25,000,000 into 4,606,596 shares of the Issuer's common stock.

F9 · underlyingValue: Nant Capital has the right at any time after December 10, 2024 and on or before December 31, 2027 to convert all or a portion of the outstanding principal amount of this Second Amended and Restated Promissory Note, as amended January 23, 2026, into fully paid and nonassessable shares of the Issuer's common stock at a price per share equal to $5.427. On March 31, 2026, Nant Capital delivered notice to the Issuer electing to convert outstanding principal in the amount of $25,000,000 into 4,606,596 shares of the Issuer's common stock.

F1 · ownership.nature: Shares held by Nant Capital, LLC, an investment vehicle of the Reporting Person.

SEC source: 0001189020-26-000008 · wk-form4_1775174919.xml · nonDerivative · entry 1

SOON-SHIONG PATRICK · CIK 0001189020 · Director · See remarks · 10% owner

CALIFORNIA CAPITAL EQUITY, LLC · CIK 0001517764 · 10% owner

Cambridge Equities, LP · CIK 0001629222 · 10% owner

MP 13 Ventures, LLC · CIK 0001629186 · 10% owner

Nant Capital, LLC · CIK 0001675758 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 251,018,873

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: Shares held by Nant Capital, LLC, an investment vehicle of the Reporting Person.

SEC source: 0001647994-26-000006 · wk-form4_1772154743.xml · nonDerivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,850,821

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024.

F2 · price: Represents the weighted average share price of an aggregate total of 75,000 shares sold in the price range of $12.00 to $12.025 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001647994-26-000004 · wk-form4_1771981423.xml · nonDerivative · entry 4

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,925,821

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024.

F4 · price: Represents the weighted average share price of an aggregate total of 165,000 shares sold in the price range of $9.89 to $10.635 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001849739-26-000004 · wk-form4_1771981555.xml · derivative · entry 3

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 67,937

Underlying: Common Stock · 25,000 shares

Expires 2032-06-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the award vested on June 12, 2023, the date immediately preceding the 2023 annual meeting of stockholders.

SEC source: 0001849739-26-000004 · wk-form4_1771981555.xml · nonDerivative · entry 2

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025.

SEC source: 0001849739-26-000004 · wk-form4_1771981555.xml · nonDerivative · entry 1

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001647994-26-000004 · wk-form4_1771981423.xml · derivative · entry 5

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,245

Underlying: Common Stock · 15,243 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

F5 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

F5 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

SEC source: 0001647994-26-000004 · wk-form4_1771981423.xml · nonDerivative · entry 3

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,090,821

F3 · price: On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld.

SEC source: 0001647994-26-000004 · wk-form4_1771981423.xml · nonDerivative · entry 2

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,096,847

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

SEC source: 0001848899-26-000005 · wk-form4_1771981509.xml · derivative · entry 3

Sachs David C. · CIK 0001848899 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,651

Underlying: Common Stock · 40,650 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

F3 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

SEC source: 0001848899-26-000005 · wk-form4_1771981509.xml · nonDerivative · entry 2

Sachs David C. · CIK 0001848899 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,143

F2 · price: On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld.

SEC source: 0001848899-26-000005 · wk-form4_1771981509.xml · nonDerivative · entry 1

Sachs David C. · CIK 0001848899 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 320,825

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

SEC source: 0001189020-26-000006 · wk-form4_1771981503.xml · derivative · entry 11

SOON-SHIONG PATRICK · CIK 0001189020 · Director · See remarks · 10% owner

CALIFORNIA CAPITAL EQUITY, LLC · CIK 0001517764 · 10% owner

Cambridge Equities, LP · CIK 0001629222 · 10% owner

MP 13 Ventures, LLC · CIK 0001629186 · 10% owner

Nant Capital, LLC · CIK 0001675758 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,329

Underlying: Common Stock · 114,329 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

F11 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

F11 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

SEC source: 0001189020-26-000006 · wk-form4_1771981503.xml · nonDerivative · entry 2

SOON-SHIONG PATRICK · CIK 0001189020 · Director · See remarks · 10% owner

CALIFORNIA CAPITAL EQUITY, LLC · CIK 0001517764 · 10% owner

Cambridge Equities, LP · CIK 0001629222 · 10% owner

MP 13 Ventures, LLC · CIK 0001629186 · 10% owner

Nant Capital, LLC · CIK 0001675758 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,757,911

F2 · price: On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld.

SEC source: 0001189020-26-000006 · wk-form4_1771981503.xml · nonDerivative · entry 1

SOON-SHIONG PATRICK · CIK 0001189020 · Director · See remarks · 10% owner

CALIFORNIA CAPITAL EQUITY, LLC · CIK 0001517764 · 10% owner

Cambridge Equities, LP · CIK 0001629222 · 10% owner

MP 13 Ventures, LLC · CIK 0001629186 · 10% owner

Nant Capital, LLC · CIK 0001675758 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,816,081

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

SEC source: 0001200637-26-000004 · wk-form4_1771981498.xml · derivative · entry 3

LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,065

Underlying: Common Stock · 4,065 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

F3 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

SEC source: 0001200637-26-000004 · wk-form4_1771981498.xml · nonDerivative · entry 2

LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,875

F2 · price: On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld.